Emerald Therapeutics

Emerald Therapeutics is a biotechnology company located in the San Francisco Bay Area, California, and was founded in 2013 by Brian Frezza and DJ Kleinbaum. The company offers a cloud based software and hardware integration platform, called the Emerald Cloud Lab (ECL), allowing researchers to perform experiments remotely in an automated lab.

The Emerald Cloud Lab provides researchers control over how experiments are carried out in the lab, and gives them the ability to adjust future lab protocols based on data generated from samples, laboratory instruments, and environmental control systems. The Emerald Cloud Lab also comes equipped with built-in tools for data analysis, manipulation, visualization, and modelling. Emerald Therapeutics claims their Emerald Cloud Lab allows scientists to achieve lower overhead costs and greater reproducibility compared to traditional laboratory experimental setups.

Funding

Series A

On December 27, 2010 Emerald Therapeutics announced their series A funding round and closed with $7,500,000 in funding from James Hong.

Series B

On March 1, 2014 Emerald Therapeutics announced their series B funding round and closed the round with $6,000,000 in funding from Schooner Capital, Founders Fund, and Max Levchin.

Series C

On June 19, 2015 Emerald Therapeutics announced raising $20,500,000 in funding during their series C funding round from Western Technology Investment, Sound Ventures, Schooner Capital, OS Fund, and Founders Fund.